Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — H.C. Andersen Capital Life Science Seminar 2023
16 slides from Expres2ion Biotech Holding Ab's conference presentation, Aug 31, 2023
Slide 1: Innovative vaccines for a healthier world
EXPRES2ION INTERIM REPORT Q1 2023 Life Science Seminar Innovative vaccines for a healthier world 31 August 2023 Hosted by E X P R E S2 I O N BIOTECHNOLOGIES ExpreS2ion Biotech Holding AB Org. Nr. 559033-3729
Slide 2: Key Historical Milestones
Key Historical Milestones Establishment of AdaptVac The company initiates a new ExpreS2ion Biotechnologies ApS ApS, enabling the use of the pipeline-focused strategy, led founded, to promote the ground-breaking Virus-Like by vaccine initiatives within proprietary ExpreS2™ technology Particle (VLP) t
Slide 3: The Business Model
The Business Model Novel Pipeline Development Independent Collaboration Fully-owned development of Partner with leading research novel protein therapeutics and organizations to source and develop ExpreS2™ Platform for vaccines novel programs Protein Expression Potential to fully acquire programs Aft
Slide 4: The Combination of Soluble Proteins and VLPs Results in Safe & Highly Effective Vaccines
The Combination of Soluble Proteins and VLPs Results in Safe & Highly Effective Vaccines Virus-like particles Replication- deficient viral Killed whole vectors virus Immunogenicity Live attenuated Soluble virus mRNA proteins Replicating viral vectors Naked DNA Peptides Safety Source: Modified A. Ros
Slide 5: ABNCoV2 – proof-of-concept for ExpreS2™ and VLP
CORONAVIRUS E X P R E S2 I O N ABNCoV2 – BIOTECHNOLOGIES proof-of-concept for ExpreS2™ and VLP Phase III primary endpoint: Non- Greater durability than approved inferiority to Pfizer mRNA vaccine vaccines across variants of concern Strong boosting effect across Stability at room temperature variants
Slide 6: Strong Market Potential
Strong Market Potential Vaccine and immuno-oncology markets are set for continued high annual growth rates The global vaccine market 1) The global Immune-Oncology market 2) • Approx. US$ 41 billions in sales 2021 • Approx. $7.5 billions in sales 2022 • Rising to US$ 67 billions by 2026 • Rising to $
Slide 7: Pipeline – Focus programs
Pipeline Focus programs Pre-clinical Disease Project / Target Discovery Pharmacology cGMP / Tox Phase 1 Phase 2 Phase 3 Market potential COVID-19 ABNCoV2/SARS-CoV-2 cVLP > 10 billion EUR BREAST CANCER ES2B-C001/Her2 cVLP > 10 billion EUR INFLUENZA MucoVax > 7 billion EUR CMV ES2B-I002 > 2 billion EU
Slide 8: Pipeline – Legacy programs
Pipeline Legacy programs Pre-clinical Disease Project / Target Discovery Pharmacology cGMP / Tox Phase 1 Phase 2 Phase 3 Market potential MALARIA >1.8 billion EUR 1: Blood-Stage RH5 2: Blood-Stage RH5-VLP 3: Transmission Pfs 48/45 4: Placenta-Borne VAR2CSA 5: Blood-Stage CYRPA complex INFLUENZA INDI
Slide 9: Strategic Review
Strategic Review Update as of 17 August 2023 • Strategic evaluation of ES2B-C001 • Certain activities to advance towards CTA readiness to continue, including the ongoing GLP preclinical safety toxicology study • Investigating strategic options • Initiating a cost reduction program • Near-term cash p
Slide 10: Second Quarter Highlights
Second Quarter Highlights • ABNCoV2 • Discovery and Exploratory ✓ Positive readout for Phase II 12-month durability ✓ CMV on track ✓ Positive readout for Phase III non-inferiority to mRNA ✓ MucoVax initiated vaccine ❑ Further advancing exploratory vaccine pipeline ❑ Pending secondary endpoint for Ph
Slide 11: Potential Income From ABNCoV2
CORONAVIRUS Potential Income From ABNCoV2 AdaptVac receives from Bavarian Nordic ExpreS2ion receives from AdaptVac • EUR 4 million upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to EUR 136 million in development and • Up to EUR 2 million in commercial milestone sales milestones payment
Slide 12: Cash Balance, 2019 – 2Q 2023 Quarterly
FINANCE Cash Balance, 2019 – 2Q 2023 Quarterly SEK millions 200 175 168 150 150 142 139 125 125 107 108 111 100 88 83 75 72 50 30 25 13 10 6 5 3 5 0 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 Innovative vaccines for a healthier world 12
Slide 13: Warrant program TO 8
Warrant program TO 8 Providing warrant holders with a valuable opportunity to be part of Expres2ion’s future endeavors Terms, timeline and exercise instructions Use of proceeds One (1) warrant of series TO 8 gives the holder the right to subscribe for one (1) new share in the company against a cash
Slide 14: Advancements Towards Key Catalysts
Advancements Towards Key Catalysts Near-term • Monetization of focus pipeline assets, primarily ES2B-C001 through partnering and ABNCoV2 through license income • Financing of new initiatives via non-dilutive financing Medium-term • Develop pipeline towards major value inflection points Long-term • S
Slide 15: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of i
Slide 16: Thank you
Thank you investor@expres2ionbio.com Innovative vaccines for a healthier world 16
ExpreS2ion Biotech Holding — H.C. Andersen Capital Life Science Seminar 2023 on 6ix